Importantly, HRP enhances losartan's therapeutic actions, confirming that PRR activation may be one of the reasons for limited anti-fibrotic effects of AT1R blockade on DN and PRR blocker may be a possible new therapy for DN. The gene discussed is AGTR1; the disease is liver dysplastic nodule.